Shopping Cart
- Remove All
Your shopping cart is currently empty
N-Desethyl Sunitinib
😃Good
Catalog No. T12145Cas No. 356068-97-8
Alias SU-11662, SU11662
N-Desethyl Sunitinib (SU012662) is the primary active metabolite of Sunitinib produced by the metabolism of cytochrome P450 enzyme 3A4 (CYP3A4).Sunitinib is an orally available inhibitor of a number of tyrosine kinases involved in tumor proliferation and angiogenesis, including VEGFR, PDGFR, KIT, and FLT3, and was approved for the treatment of advanced/metastatic renal cell carcinoma (RCC)
N-Desethyl Sunitinib
😃Good
Catalog No. T12145Alias SU-11662, SU11662Cas No. 356068-97-8
N-Desethyl Sunitinib (SU012662) is the primary active metabolite of Sunitinib produced by the metabolism of cytochrome P450 enzyme 3A4 (CYP3A4).Sunitinib is an orally available inhibitor of a number of tyrosine kinases involved in tumor proliferation and angiogenesis, including VEGFR, PDGFR, KIT, and FLT3, and was approved for the treatment of advanced/metastatic renal cell carcinoma (RCC)
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | 73 € | In Stock | |
| 1 mL x 10 mM (in DMSO) | 144 € | 7-10 days |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "N-Desethyl Sunitinib"
Axitinib
Cited
AG-013736
T1452319460-85-0
Axitinib (AG-013736) is a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1, VEGFR2, VEGFR3, and PDGFRβ (IC50=4/20/0.4/2 nM). Axitinib has antitumor activity and is used in the treatment of renal cell carcinoma.
- 31 €
Size
QTY
CitedSorafenib Cited
Bay 43-9006
T0093L284461-73-0
Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.
- 32 €
Size
QTY
CitedIsobutyl Butyrate
T203881539-90-2
Isobutyl Butyrate is a butyrate ester formed by the condensation of butyric acid with isobutyl alcohol, which is a metabolite of rifampicin, an antibiotic of rifamycins.Isobutyl Butyrate is a fruity organic compound used mainly in the formulation of flavors.
- 28 €
Size
QTY
Gilteritinib Cited
ASP2215
T44091254053-43-4
Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
- 32 €
Size
QTY
CitedMycophenolate Mofetil Cited
TM-MMF, RS 61443
T6293128794-94-5
Mycophenolate Mofetil (TM-MMF), an immunosuppressive agent, is the 2-morpholinoethyl ester of mycophenolic acid (MPA), and an inhibitor of inosine monophosphate dehydrogenase (IMPDH).
- 44 €
Size
QTY
CitedClozapine N-Oxide Cited
T449434233-69-7
Clozapine N-oxide is the major metabolite of Clozapine and is blood-brain barrier permeable. Clozapine N-oxide is an agonist of DREADDs and activates the DREADD receptors hM3Dq and hM4Di. Clozapine N-oxide is also a dopamine antagonist and selective muscarinic M4 receptor agonist.
- 28 €
Size
QTY
CitedTulipalin A
α-methylene-γ-butyrolactone, 2-Methylenebutyrolactone
T5320547-65-9
Tulipalin A (α-methylene-γ-butyrolactone) (2-Methylenebutyrolactone) which has some phytotoxicity is a natural compound extracted from Tulipa gesneriana.
- 36 €
Size
QTY
Regorafenib Cited
Fluoro-Sorafenib, BAY 73-4506
T1792755037-03-7
Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ, exhibiting both antitumor and anti-angiogenic activity.
- 28 €
Size
QTY
CitedAmpyrone
Solnapyrin-A, NSC 60242, Minoazophene, Aminoantipyrin, 4-Aminoantipyrine
T005083-07-8
Ampyrone (4-Aminoantipyrine) is a reagent for glucose determination in the presence of peroxidase and phenol.
- 33 €
Size
QTY
Pazopanib
GW786034
T0097L444731-52-6
Pazopanib (GW786034) is an inhibitor of protein tyrosine kinases that inhibits VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms (IC50=10/30/47/84/74/140/146 nM). Pazopanib has antitumor activity.
- 39 €
Size
QTY
Isonicotinic acid
Fr1375655-22-1
Isonicotinic acid, a metabolite of isoniazid and a useful isomer of nicotinic acid, is formed from isoniazid by hydrazinolysis and can be catalyzed by cytochrome P450 enzymes, such as CYP2C.
- 50 €
Size
QTY
Sunitinib Cited
SU 11248
T0374L557795-19-4
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80/2 nM). It exhibits antitumor activity and is used for treating kidney cancer and gastrointestinal tumors.
- 50 €
Size
QTY
CitedSelect Batch
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | N-Desethyl Sunitinib (SU012662) is the primary active metabolite of Sunitinib produced by the metabolism of cytochrome P450 enzyme 3A4 (CYP3A4).Sunitinib is an orally available inhibitor of a number of tyrosine kinases involved in tumor proliferation and angiogenesis, including VEGFR, PDGFR, KIT, and FLT3, and was approved for the treatment of advanced/metastatic renal cell carcinoma (RCC) |
| Alias | SU-11662, SU11662 |
| Molecular Weight | 370.42 |
| Formula | C20H23FN4O2 |
| Cas No. | 356068-97-8 |
| Smiles | C(=C\1/C=2C(NC1=O)=CC=C(F)C2)\C3=C(C)C(C(NCCNCC)=O)=C(C)N3 |
| Relative Density. | 1.265 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
| Solubility Information | DMSO: 4 mg/mL (10.8 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Sci Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy N-Desethyl Sunitinib | purchase N-Desethyl Sunitinib | N-Desethyl Sunitinib cost | order N-Desethyl Sunitinib | N-Desethyl Sunitinib chemical structure | N-Desethyl Sunitinib formula | N-Desethyl Sunitinib molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.